1
|
Matsubara K, Miyoshi K, Takeshi K, Kawana S, Kubo Y, Shimizu D, Hashimoto K, Tanaka S, Okazaki M, Sugimoto S, Toyooka S. A Novel Strategy In Vivo Lung Recovery for Prompt Recovery from Primary Graft Dysfunction after Lung Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
2
|
Choshi H, Miyoshi K, Ujike H, Kawana S, Kubo Y, Shimizu D, Matsubara K, Hashimoto K, Tanaka S, Shien K, Suzawa K, Yamamoto H, Okazaki M, Sugimoto S, Toyooka S. Successful Lung Re-Transplantation with Perioperative Desensitization for Sensitized Recipient with Donor Specific DQ Antibody. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Kubo Y, Sugimoto S, Choshi H, Ujike H, Kawana S, Shimizu D, Matsubara K, Hashimoto K, Tanaka S, Shien K, Suzawa K, Miyoshi K, Yamamoto H, Okazaki M, Toyooka S. Histidine-Rich Glycoprotein Ameliorates Lung Ischemia-Reperfusion Injury in a Mouse. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
4
|
Ujike H, Tanaka S, Choshi H, Kawana S, Kubo Y, Shimizu D, Matsubara K, Hashimoto K, Shien K, Suzawa K, Miyoshi K, Yamamoto H, Okazaki M, Sugimoto S, Toyooka S. Bilateral Lung Transplantation from Living Donors in a 67-Year-Old Patient. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
5
|
Fernandez M, Kop M, Terada K, Shimizu D, Vierkoetter KR. Squamous Cell Carcinoma of the Vulva: Clinicopathologic Features of Human Papillomavirus (HPV) Associated and Independent Lesions. Am J Clin Pathol 2022. [DOI: 10.1093/ajcp/aqac126.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Abstract
Introduction/Objective
Vulvar squamous cell carcinoma (VSCC) develops via HPV-associated and HPV-independent pathways. Each subset is notable for distinct precursor lesions, morphology, epidemiology and prognoses. There is no consensus regarding the incidence of HPV-associated VSCC, although the literature estimates a range of 15–79%. The current investigation aims to determine the incidence and clinicopathologic features of HPV-associated and HPV- independent VSCC in a diverse, multi-ethnic population.
Methods/Case Report
Resections specimens of VSCC from 1991 to 2020 were retrospectively identified. Cases were reviewed for confirmation of diagnosis, followed by immunohistochemical staining for p16. Age at diagnosis, ethnicity, body mass index, smoking history, tumor size, depth of invasion, and stage were obtained. Statistical analyses included t and Fisher’s exact tests as appropriate, with p<0.05 considered statistically significant.
Results (if a Case Study enter NA)
Sixty-seven VSCC cases were reviewed. By immunohistochemistry, 34 (51%) were HPV-associated. Age at diagnosis was statistically significant (p = 0.0008), with an average age of 63 years for HPV-associated and 75 years for HPV-independent VSCC.Tumor size approached statistical significance (p = 0.0577), with larger tumors occurring in the absence of HPV. Additionally, the incidence of HPV-independent VSCC nearly doubled every 10 years while the incidence of HPV-associated VSCC remained constant.
Conclusion
In this diverse, multi-ethnic cohort, the incidence of HPV-associated VSCC (51%) is at the higher end of the global range of 15-79%. Differences in age demonstrated statistical significance, supporting existing data describing HPV-associated VSCC diagnosed in relatively younger women. Tumor size approached statistical significance, signaling a correlation between HPV-independent VSCC and larger tumors; findings that may support reports of HPV-independent VSCC being associated with a worse prognosis. The increasing incidence of HPV- independent VSCC compared to a constant rate of HPV-associated VSCC suggests changing patterns of detection and pathogenesis.
Collapse
Affiliation(s)
- M Fernandez
- Pathology, University of Hawaii John A. Burns School of Medicine Hawaii Residency Program , Honolulu, Hawaii , United States
| | - M Kop
- The Queen’s Medical Center , Honolulu, Hawaii , United States
| | - K Terada
- University of Hawaii John A. Burns School of Medicine Department of Obstetrics, Gynecology and Women’s Health , Honolulu, Hawaii , United States
| | - D Shimizu
- University of Hawaii John A. Burns School of Medicine Department of Pathology , Honolulu, Hawaii , United States
| | - K R Vierkoetter
- University of Hawaii John A. Burns School of Medicine Department of Pathology , Honolulu, Hawaii , United States
| |
Collapse
|
6
|
Tomioka Y, Sugimoto S, Kawana S, Kubo Y, Shimizu D, Matsubara K, Tanaka S, Miyoshi K, Okazaki M, Toyooka S. Identification of Single-Nucleotide Polymorphisms Associated with Renal Dysfunction After Lung Transplantation Using Ethnic-Specific SNP Array. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
7
|
Kubo Y, Sugimoto S, Shiotani T, Kawana S, Shimizu D, Matsubara K, Hashimoto K, Tanaka S, Shien K, Suzawa K, Miyoshi K, Yamamoto H, Okazaki M, Toyooka S. The Percentage of Low Attenuation Area on Computed Tomography to Detect Chronic Lung Allograft Dysfunction After Bilateral Lung Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Shimizu D, Okazaki M, Sugimoto S, Kinoshita R, Kawana S, Kubo Y, Matsubara K, Nakata K, Matsukawa A, Sakaguchi M, Toyooka S. Inhibiting S100A8/A9 Attenuates Airway Obstruction in a Mouse Heterotopic Tracheal Transplantation Model. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Otani S, Tomioka Y, Matsubara K, Shimizu D, Yamamoto H, Shiotani T, Suzawa K, Miyoshi K, Yamamoto H, Okazaki M, Sugimoto S, Yamane M, Toyooka S. Pediatric Lung Transplantation−Intermediate Outcomes of a Japanese Center. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Matsubara K, Otani S, Shimizu D, Tomioka Y, Shiotani T, Yamamoto H, Miyoshi K, Okazaki M, Sugimoto S, Yamane M, Toyooka S. Risk Assessment of Chronic Lung Allograft Dysfunction Phenotypes after Living-Donor Lobar Lung Transplantation According to the 2019 ISHLT Classification System. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
11
|
Yamamoto H, Sugimoto S, Suzuki E, Tomioka Y, Shiotani T, Shimizu D, Matsubara K, Miyoshi K, Otani S, Okazaki M, Yamane M, Toyooka S. Combination of Neutrophil to Lymphocyte Ratio and Glasgow Prognostic Score Improves Prognostic Accuracy in Lung Transplantation: Validation of 9 Preoperative Prognostic Scoring Methods. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Shiotani T, Sugimoto S, Yamamoto H, Matsubara K, Shimizu D, Nakata K, Tomioka Y, Miyoshi K, Otani S, Okazaki M, Yamane M, Toyooka S. Plasma Levels of Histidine-Rich Glycoprotein are Associated with the Development of Primary Graft Dysfunction after Lung Transplantation. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
13
|
Tomioka Y, Sugimoto S, Matsubara K, Shimizu D, Yamamoto H, Shiotani T, Miyoshi K, Ohtani S, Okazaki M, Yamane M, Toyooka S. The UNCX Polymorphism is Associated with the Development of Renal Dysfunction after Lung Transplantation. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Shimizu D, Kataoka M, Okutani D, Watanabe K, Kawai H, Harita S. P06.02 Prognostic Factors and Strategies for Metachronous Second Primary Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Shiotani T, Sugimoto S, Yamamoto H, Shimizu D, Miyoshi K, Otani S, Okazaki M, Yamane M, Oto T, Toyooka S. Plasma micro-RNA Levels are Associated with the Development of Chronic Lung Allograft Dysfunction after Bilateral Living-Donor and Cadaveric Lung Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
16
|
Masuda N, Ohtani S, Nagai S, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Takahashi M. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Takami H, Niwa Y, Yamada S, Fujii T, Sugimoto H, Kodera Y. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. Br J Surg 2018; 105:1349-1358. [PMID: 29741294 DOI: 10.1002/bjs.10876] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 02/11/2018] [Accepted: 03/16/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND Peritoneal metastasis is a frequent cause of death in patients with gastric cancer. The aim of this study was to identify molecules responsible for mediating peritoneal metastasis of gastric cancer. METHODS Transcriptome and bioinformatics analyses were conducted to identify molecules associated with peritoneal metastasis. The therapeutic effects of intraperitoneally administered small interfering (si) RNA were evaluated using mouse xenograft models. Expression of mRNA and protein was determined in gastric tissues from patients with gastric cancer. RESULTS Synaptotagmin XIII (SYT13) was expressed at significantly higher levels in patients with peritoneal recurrence, but not in those with hepatic or distant lymph node recurrence. Inhibition of SYT13 expression in a gastric cancer cell line transfected with SYT13-specific siRNA (siSYT13) was associated with decreased invasion and migration ability of the cells, but not with proliferation and apoptosis. Intraperitoneal administration of siSYT13 significantly inhibited the growth of peritoneal nodules and prolonged survival in mice. In an analysis of 200 patients with gastric cancer, SYT13 expression in primary gastric cancer tissues was significantly greater in patients with peritoneal recurrence or metastasis. A high level of SYT13 expression in primary gastric cancer tissues was an independent risk factor for peritoneal recurrence. CONCLUSION SYT13 expression in gastric cancer is associated with perioneal metatases and is a potential target for treatment.
Collapse
Affiliation(s)
- M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Shimizu
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Tanaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - C Tanaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Kobayashi
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Hayashi
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Takami
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
18
|
Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P5-16-04: A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: This study aimed to evaluate response to neoadjuvant chemotherapy (NAC) for patients with hormone receptor-negative (HR-negative) breast cancer (BC) to identify subtypes that require anthracycline treatment.
Methods: In total, 103 patients with operable HR-negative BC were registered. They were randomely assigned to administration of 6 cycles of docetaxel (75mg/m2) and cyclophosphamide (600 mg/m2) (TC6) or 3 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100mg/m2), and cyclophosphamide (500mg/m2) followed by 3 cycles of docetaxel (100mg/m2) (FEC-D). Cytokeratin (CK) 5/6 and EGFR expression were used to identify basal and non-basal triple-negative (TN) BC. The primary endpoint was pathological complete response (pCR); secondary endpoints were safety, breast-conserving surgery, disease-free survival, and overall survival. Predictive factors of pCR for each regimen were also evaluated.
Results:
The pCR rate was 36% for FEC-D and 25.5% for TC6, which did not differ significantly (P=0.265). When TN BC was subdivided into basal and non-basal subtypes, the pCR rate in the basal subtype was significantly lower for TC6 (13.6%) than for FEC-D (42.9%) (P=0.033), but did not significantly differ in the non-basal (TC6, 36.4%; FEC-D, 25.0%) and HER2-positive (TC6, 41.7%; FEC-D, 35.7%) cases.
The relative dose intensities of epirubicin and docetaxel in FEC-D and docetaxel in TC6 were 96.3±13.0%, 93.5±14.6%, and 93.9±16.3% (mean±SD), respectively. Occurrence of grade ≥2 adverse events was significant in FEC-D-treated patients. Poor appetite (P<0.001), nausea (P<0.001), vomiting (P<0.001), dysgeusia (P=0.03), and fatigue (P=0.05) were significantly more common for FEC-D than TC6. Patients treated with FEC-D experienced significantly more febrile neutropenia and anemia (P=0.016 and 0.017, respectively).
The rates of breast-conserving surgery were 68.0 and 72.3% for FEC-D and TC6, respectively (P=0.641).
Patients achieved pCR had better DFS (log rank test, P = 0.287) and OS (log rank test, P = 0.069), though not significant. Patients treated with FEC-D had better DFS (log rank test, P = 0.107) and OS (log rank test, P = 0.159), though not significant. Among patients with TN BC, those treated with FEC-D had significantly better DFS (log rank test, P = 0.016) and OS (log rank test, P = 0.034) than treated with TC6.
Low ALDH1 expression and high topo IIα protein expression were strongly correlated with pCR in FEC-D, with odds ratios (ORs) of 4.33 [95% CI, 1.02–18.38] and 4.08 [0.97–17.2], respectively. ALDH1 was also associated with pCR in TC, OR=3.50 [0.84–14.6]. Other factors, including age, tumor size, nodal status, tumor grade, Ki67, p53, and TOP 2A status were not associated with pCR in either regimen.
Conclusions:We found that TC6 was less effective than FEC-D for treating HR-negative BC because it was insufficient for TNBC, particularly for basal BC. This suggests that anthracycline is more important than taxane for basal BC. Additionally, ALDH1 could be a marker for resistance to conventional chemotherapy.
Citation Format: Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- K Narui
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ishikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - D Shimizu
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Tanabe
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Sasaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - MS Oba
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Morita
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Nawata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Kida
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Mogaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Doi
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Tsugawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Ogata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ota
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Kosaka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - N Sengoku
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Kuranami
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Saito
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Suzuki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - A Suto
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Arioka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Chishima
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Ichikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - I Endo
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Tokuda
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| |
Collapse
|
19
|
Murata K, Kanemura N, Kokubun T, Fujino T, Morishita Y, Onitsuka K, Fujiwara S, Nakajima A, Shimizu D, Takayanagi K. Controlling joint instability delays the degeneration of articular cartilage in a rat model. Osteoarthritis Cartilage 2017; 25:297-308. [PMID: 27756697 DOI: 10.1016/j.joca.2016.10.011] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 09/26/2016] [Accepted: 10/10/2016] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Joint instability induced by anterior cruciate ligament (ACL) transection is commonly considered as a predisposing factor for osteoarthritis (OA) of the knee; however, the influence of re-stabilization on the protection of articular cartilage is unclear. The aim of this study was to evaluate the effect of joint re-stabilization on articular cartilage using an instability and re-stabilization ACL transection model. DESIGN To induce different models of joint instability, our laboratory created a controlled abnormal joint movement (CAJM) group and an anterior cruciate ligament transection group (ACL-T). Seventy-five Wistar male rats were randomly assigned to the CAJM (n = 30), ACL-T (n = 30), or no treatment (INTACT) group (n = 15). Cartilage changes were assessed with soft X-ray analysis, histological and immunohistochemistry analysis, and real-time polymerase chain reaction (PCR) analysis at 2, 4, and 12 weeks. RESULTS Joint instability, as indicated by the difference in anterior displacement between the CAJM and ACL-T groups (P < 0.001), and cartilage degeneration, as evaluated according to the Osteoarthritis Research Society International (OARSI) score, were significantly higher in the ACL-T group than the CAJM group at 12 weeks (P < 0.001). Moreover, joint re-stabilization maintained cartilage structure (thickness [P < 0.001], surface roughness [P < 0.001], and glycosaminoglycan stainability [P < 0.001]) and suppressed tumor necrosis factor-alpha (TNF-α) and caspase-3 at 4 weeks after surgery. CONCLUSION Re-stabilization of joint instability may suppress inflammatory cytokines, thereby delaying the progression of OA. Joint instability is a substantial contributor to cartilage degeneration.
Collapse
Affiliation(s)
- K Murata
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan; Department of Physical Therapy, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan
| | - N Kanemura
- Department of Physical Therapy, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan.
| | - T Kokubun
- Department of Physical Therapy, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan
| | - T Fujino
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan
| | - Y Morishita
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan
| | - K Onitsuka
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan
| | - S Fujiwara
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan
| | - A Nakajima
- Graduate Course of Health and Social Services, Graduate School of Saitama Prefectural University, Saitama, Japan
| | - D Shimizu
- Department of Physical Therapy, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan
| | - K Takayanagi
- Department of Physical Therapy, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan
| |
Collapse
|
20
|
Oya H, Kanda M, Koike M, Iwata N, Niwa Y, Shimizu D, Takami H, Sueoka S, Hashimoto R, Ezaka K, Nomoto S, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2016; 29:663-9. [PMID: 25951896 DOI: 10.1111/dote.12373] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Despite improvements in surgical techniques, perioperative management, and multidisciplinary therapy, treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) remain poor. Therefore, development of novel molecular biomarkers, which either predict patient survival or become therapeutic targets, is urgently required. In the present study, to facilitate early detection of ESCC and predict its clinical course, we investigated the relationship of the serum level of melanoma-associated antigen (MAGE)-D4 to patients' clinicopathological characteristics. Using quantitative real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assays, we determined the levels of MAGE-D4 mRNA and protein in cell lysates and conditioned medium of cultures, respectively, of nine ESCC cell lines. Further, we determined MAGE-D4 levels in serum samples collected from 44 patients with ESCC who underwent radical esophagectomy without neoadjuvant therapy as well as from 40 healthy volunteers. Samples of conditioned medium and cell lysates contained comparable levels of MAGE-D4 that correlated closely with the levels of MAGE-D4 mRNA. Preoperative MAGE-D4 levels in the sera of 44 patients with ESCC, which varied from 0 to 2,354 pg/mL (314 ± 505 pg/mL, mean ± standard deviation), were significantly higher compared with those of healthy volunteers. By setting the cutoff at the highest value for healthy volunteers (50 pg/mL), the MAGE-D4-positive group of patients was more likely to have shorter disease-specific and disease-free survival compared with those of the MAGE-D4-negative group, although the differences were not statistically significant. Our results indicate that the elevation of preoperative serum MAGE-D4 levels in some patients with ESCC was possibly caused by excess production of MAGE-D4 by tumor cells followed by its release into the circulation. Clinical implications of serum MAGE-D4 levels should be validated in a large population of patients with ESCC.
Collapse
Affiliation(s)
- H Oya
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Koike
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Iwata
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Shimizu
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Takami
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Sueoka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Hashimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Ezaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Nomoto
- Department of Surgery, Aichi-Gakuin University School of Dentistry, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - G Nakayama
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Fujiwara
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
21
|
Fujimoto H, Ishikawa T, Satake T, Ko S, Shimizu D, Narui K, Yamada A, Sasaki T, Nagashima T, Endo I, Miyazaki M. Donor site selection and clinical outcomes of nipple-areola skin-sparing mastectomy with immediate autologous free flap reconstruction: A single-institution experience. Eur J Surg Oncol 2015; 42:369-75. [PMID: 26792708 DOI: 10.1016/j.ejso.2015.12.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 11/14/2015] [Accepted: 12/01/2015] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND The objective of this study was to examine the clinical outcomes of immediate breast reconstruction using perforator flaps from different donor sites, and to characterize the trends among these flaps. METHODS We retrospectively reviewed 136 consecutive patients who underwent immediate breast reconstruction using free flaps after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM). The whole breast was pathologically analyzed in 5-mm sections. Breast reconstruction was performed using the deep inferior epigastric perforator (DIEP) flap, gluteal artery perforator (GAP) flap, and posterior medial thigh perforator (PMTP) flap. Patient characteristics were compared among donor sites. RESULTS NSM was converted to SSM because of intraoperative subareolar tumor positivity in 7 of 107 patients. Eleven patients had positive margins in permanent sections. All but one patient had a positive horizontal margin in the peripheral direction. The 5-year recurrence-free survival rate was 91.9%. The locoregional recurrence rate was 5.1% with a mean follow-up observation period of 75 months. DEIP, GAP, and PMTP flaps were used in 64 (47.1%), 38 (27.9%), and 34 (25.0%) patients, retrospectively. DIEP flaps were used in older patients and those with a higher body mass index. GAP flaps were used in younger patients. DIEP and GAP flaps were used for larger breasts, and PMTP flaps for smaller breasts. CONCLUSION NSM or SSM with immediate perforator flap breast reconstruction is an oncologically acceptable surgical option. We believe that age, desire to have children, body mass index, and excised breast volume are valuable factors for selecting the optimal donor site.
Collapse
Affiliation(s)
- H Fujimoto
- Department of General Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-0856, Japan; Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan; Department of Breast Surgery, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350-8550, Japan.
| | - T Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Satake
- Department of Plastic Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - S Ko
- Department of Plastic Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - D Shimizu
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - K Narui
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Sasaki
- Department of Pathology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Nagashima
- Department of General Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-0856, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - M Miyazaki
- Department of General Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-0856, Japan
| |
Collapse
|
22
|
Kida K, Ishikawa T, Yamada A, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y, Endo I. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer. Eur J Surg Oncol 2015; 41:566-70. [PMID: 25650249 DOI: 10.1016/j.ejso.2014.10.066] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 10/08/2014] [Accepted: 10/17/2014] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Although sentinel lymph node biopsy (SLNB) is a standard staging method for assessing nodal status of breast cancer patients, SLNB after neoadjuvant chemotherapy (NAC) remains controversial. The aim of this study was to validate the practicality and accuracy of SLNB by our modified Indigocarmine blue dye methods following NAC. METHODS One hundred consecutive cases with breast cancers treated by NAC were enrolled in this study. After NAC, all patients underwent SLNB performed by our modified Indigocarmine blue dye methods without radioisotope, followed by back-up axillary lymph node dissection (ALND). RESULTS Sentinel nodes (SNs) were identified in 94 cases (identification rate, 94%); the accuracy was 94.7% (89/94 cases); and the false negative rate (FNR) 13.5% (5/37 cases). For cases with vs. without clinically evident metastatic nodes before NAC, the identification rate was 92.4% (61/66 cases) vs. 97.1% (33/34 cases); the accuracy 91.8% (56/61 cases) vs. 97.0% (32/33 cases) and the FNR 16.1% (5/31 cases) vs. 0% (0/6 case), respectively. There were six patients without identified SNs, three of them had metastatic nodes. False negatives occurred in five cases; in four, fewer than two sentinel nodes had been removed. CONCLUSION Following NAC, the accuracy of SLNB by modified Indigocarmine blue dye methods is adequate compared with other tracers. In patients in whom no SNs have been identified, lymphatic metastasis is likely and therefore ALND is recommended. For patients with cN0 prior to NAC, SLNB by modified Indigocarmine blue dye methods is clinically feasible, though controversial for patients with positive nodes.
Collapse
Affiliation(s)
- K Kida
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
| | - T Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - D Shimizu
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - M Tanabe
- Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
| | - T Sasaki
- Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
| | - Y Ichikawa
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
23
|
Narui K, Ishikawa T, Satake T, Adachi S, Yamada A, Shimada K, Shimizu D, Kida K, Sugae S, Ichikawa Y, Tanabe M, Sasaki T, Endo I. Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy. Eur J Surg Oncol 2014; 41:94-9. [PMID: 25245538 DOI: 10.1016/j.ejso.2014.09.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Revised: 08/15/2014] [Accepted: 09/01/2014] [Indexed: 10/24/2022] Open
Abstract
BACKGROUND The impact of neoadjuvant chemotherapy (NACT) on immediate free flap breast reconstruction remains controversial. Furthermore, the oncological outcomes of immediate free flap breast reconstruction after skin-sparing mastectomy (SSM) following NACT remain unclear. This study aimed to investigate the surgical complications and oncological outcomes of immediate perforator flap reconstruction after SSM following NACT. METHODS A total of 201 consecutive patients with indications for immediate perforator flap reconstruction after SSM were included between 2004 and 2012. Surgical and oncological outcomes were compared between patients with and without NACT. RESULTS There were 38 patients in the NACT group and 163 in the non-NACT control group. The median age of the NACT group was 39.5 years, which was significantly younger than the control group (43.0 years; P < 0.05). Patients in the NACT group also had more advanced and aggressive disease (P < 0.05). There was no significant difference in the frequency of surgical complications between the groups, no difference in the type of complications, and no significant difference in the frequencies of major and minor complications. No patients in the NACT group had delayed adjuvant therapy. Eight patients (4%) developed recurrences, with a median follow-up time of 3.0 years. Local recurrences occurred in three control patients but no patients in the NACT group. CONCLUSION NACT does not affect short-term or interim outcomes after immediate perforator flap reconstruction and may thus represent a safe and practical treatment option for the multidisciplinary treatment of breast cancer.
Collapse
Affiliation(s)
- K Narui
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan.
| | - T Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Satake
- Department of Plastic Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - S Adachi
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - K Shimada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - D Shimizu
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - K Kida
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - S Sugae
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Y Ichikawa
- Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - M Tanabe
- Department of Pathology, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Sasaki
- Department of Pathology, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| |
Collapse
|
24
|
Kanda M, Shimizu D, Sugimoto H, Oya H, Hibino S, Takami H, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. B-Cell Translocation Gene 1 Serves As a Novel Prognostic Indicator of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Shimizu D, Kanda M, Sugimoto H, Oya H, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. Identification of Intragenic Methylation in the Tusc1 Gene As a Novel Prognostic Marker of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Ishikawa T, Shimizu D, Tanabe M, Oba MS, Sasaki T, Morita S, Kida K, Nawata S, Mogami M, Doi T, Tsugawa K, Ogata H, Kosaka Y, Sengoku N, Saito Y, Suzuki Y, Suto A, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P3-14-08: A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taxane-based regimens have been developed and used widely to treat breast cancer. It has therefore become important to identify subgroups of patients in which anthracyclines are indispensable. Pathological response to neoadjuvant chemotherapy (NAC) predicts prognosis in hormone-negative subtypes. We therefore initiated a randomized phase II NAC study to compare a taxane with and without an anthracycline in these breast-cancer subtypes.
Aim: To determine the safety and activity of six cycles of docetaxel and cyclophosphamide (TC6) compared with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D), and to examine the predictive factors for each regimen.
Methods: Eligibility criteria were operable hormone-receptor-negative breast cancer, age younger than 75 years and ECOG PS0-1. According to HER2 status, patients were randomly assigned to TC (75/600 mg/m2) every 3 weeks X 6 or FEC (500/100/500 mg/m2) every 3 weeks X 3 followed by D (100 mg/m2) every 3 weeks X 3. The primary endpoint was the rate of pathological complete response (pCR; grade 3). Triple-negative (TN) breast cancer was subdivided by cytokeratin 5/6 and epidermal growth factor receptor into basal- and non-basal subtypes. Secondary endpoints were safety, breast-conserving surgery, disease-free survival, overall survival, and predictive factors: Ki-67, p53, aldehyde dehydrogenase (ALDH) 1 and topoisomerase 2A by both immunohistochemistry and fluorescence in situ hybridization for each regimen.
Results: Ninety-seven of 103 patients were analyzed successfully (50 for FEC-D and 47 for TC6). Significantly more severe adverse events (grade 2) were observed in FEC-D-treated patients (poor appetite, nausea and vomiting: p = 0.001; febrile neutropenia: p = 0.016). The pCR rate tended to be higher in FEC-D-treated patients compared with TC6-treated patients (pCR: 36.0 vs. 25.5%, n.s.). FEC-D treatment was significantly more effective than TC6 in basal-type (p = 0.033) but not in non-basal and HER2 subtypes. ALDH1 was associated with resistance to both regimens (FEC-D: p = 0.047, TC6: p = 0.085)
Conclusions: TC6 was safer, but not more effective than FEC-D. TC6 was significantly less active than FEC-D in basal subtype, and equivalent to FEC-D in HER2 and non-basal subtypes. Concurrent use of trastuzumab with TC could thus represent a reasonable option for NAC in HER2-subtype patients. ALDH1 could provide a marker for novel strategies such as stem cell-based therapies for breast cancer. Analyses on pathological factors in surgical specimens after NAC will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-08.
Collapse
Affiliation(s)
- T Ishikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - D Shimizu
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Tanabe
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - MS Oba
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Sasaki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Morita
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Kida
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Nawata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Mogami
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Doi
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Tsugawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - H Ogata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Kosaka
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - N Sengoku
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Saito
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Suzuki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Suto
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Chishima
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Ichikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - I Endo
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Tokuda
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| |
Collapse
|
27
|
Oya H, Kanda M, Takami H, Hibino S, Shimizu D, Niwa Y, Koike M, Nomoto S, Yamada S, Nishikawa Y, Asai M, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus 2013; 28:188-95. [PMID: 24147998 DOI: 10.1111/dote.12156] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
To pursue an urgently needed treatment target for esophageal cancer (EC), we investigated the function of the recently discovered melanoma-associated antigen (MAGE)-D4 in squamous cell EC. MAGE-D4 messenger RNA (mRNA) expression was analyzed in nine EC cell lines using quantitative reverse transcription polymerase chain reaction. In 65 surgical specimens of squamous cell EC with no prior neoadjuvant therapy, MAGE-D4 mRNA expression in EC tissues and corresponding normal tissues was analyzed and compared, and evaluated in terms of clinicopathological factors. In representative cases, MAGE-D4 protein distribution was analyzed immunohistochemically. The heterogeneity of MAGE-D4 mRNA expression was confirmed in EC cell lines by quantitative reverse transcription polymerase chain reaction. In surgical specimens, MAGE-D4 mRNA expression was significantly higher in EC tissues than in corresponding normal tissues (P < 0.001). Patients with the highest MAGE-D4 mRNA expression in EC tissues (top quartile, n = 17) had significantly shorter overall survival than patients with low expression (2-year survival: 44% and 73%, respectively, P = 0.006). Univariate analysis identified age (≥65 years), lymphatic involvement, and high MAGE-D4 mRNA expression as significant prognostic factors; high MAGE-D4 mRNA expression was also an independent prognostic factor in multivariable analysis (hazard ratio: 2.194; P = 0.039) and was significantly associated with Brinkman index (P = 0.008) and preoperative carcinoembryonic antigen level (P = 0.002). Immunohistochemical MAGE-D4b expression was consistent with MAGE-D4 mRNA profiling. Our results suggest that MAGE-D4 overexpression influences tumor progression, and MADE-D4 can be a prognostic marker and a potential molecular target in squamous cell EC.
Collapse
Affiliation(s)
- H Oya
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Terada K, Black M, Davis J, Terada L, Shimizu D. The effect of loss of mismatch repair gene expression on survival for patients with high risk endometrial cancer. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Aoyagi T, Nagahashi M, Chishima T, Sasaki T, Ichikawa Y, Takabe K, Endo I. ATP-binding Cassette Transporter ABCC11 is Highly Expressed in Aggressive Breast Cancer Subtypes and Related With Worse Disease-free Survival. J Surg Res 2013. [DOI: 10.1016/j.jss.2012.10.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Sakuma T, Maurin C, Shimizu D, Shinohara S. [Cryptorchidism associated with ectopic adrenal cortical tissue in the spermatic cord in a 51-year-old male]. Prog Urol 2012. [PMID: 23178102 DOI: 10.1016/j.purol.2012.09.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
This case report describes an exceptional case of ectopic adrenal cortex tissue (EACT) in the spermatic cord associated with ipsilateral cryptorchidism in an adult. While both EACT and cryptorchidism are fairly common congenital anomalies in boys, adult cases are uncommon. Although the spermatic cord is a known site of EACT, the reports of its association with cryptorchidism have been limited to child cases. During surgery, undescended testis was discovered and incidentally ectopic adrenal tissue along the spermatic cord was also identified. This combination of developmental aberrations in the adult has not been described, and the clinicopathological findings are reported with a brief literature review.
Collapse
Affiliation(s)
- T Sakuma
- Service de médecine de laboratoire, hôpital Atsumi, Akaishi, Kanbe, Tahara, Aichi, Japan.
| | | | | | | |
Collapse
|
31
|
Hachisuka T, Kinoshita T, Yamakawa T, Kurata N, Tsutsuyama M, Umeda S, Tokunaga S, Yarita A, Shibata M, Shimizu D, Shikano T, Hattori K, Mori T, Shinohara M, Miyauchi M. Transumbilical laparoscopic surgery using GelPort through an umbilical zigzag skin incision. Asian J Endosc Surg 2012. [PMID: 22776345 DOI: 10.1111/j.1758-5910] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION We report herein a new method of transumbilical laparoscopic surgery using a GelPort through an umbilical zigzag skin incision. The method involves collaborating with plastic surgeons to ensure the procedure was minimally invasive. MATERIALS AND SURGICAL TECHNIQUE After marking a zigzag skin incision in the umbilical region, the skin was incised along this line. Then, a GelPort double-ring wound retractor was inserted through the incision, which enlarged the diameter of the fascial opening to 6 cm. The Gelport was latched on the wound retractor ring, following the inflation of the pneumoperitoneum by CO (2). One or more additional ports were inserted as necessary. All operations were performed in the standard fashion. The specimen was easily extracted from the abdomen through the umbilical incision, and anastomosis was performed. Using the above method, we performed the following procedures: one total gastrectomy, one distal gastrectomy, three gastric local resections, five right hemicolectomies, two high anterior resections, three cholecystectomies, and seven transabdominal preperitoneal hernioplasties. All cases were accomplished without any complications using this method. The wounds of the umbilical region were almost "scarless" in all cases. DISCUSSION We developed an umbilical zigzag skin incision technique to perform abdominal laparoscopic operations using a GelPort, with a minimal number of skin incisions. We consider that our method reduces the technical difficulties associated with laparoscopic surgery and maintains cosmesis.
Collapse
Affiliation(s)
- T Hachisuka
- Department of General Surgery, Yokkaichi Municipal Hospital, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Grzankowski K, Kimata C, Shimizu D, Terada K. Mismatch repair gene loss of expression and microsatellite instability in endometrial cancer found to be more prevalent with lower body mass index. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Hachisuka T, Kinoshita T, Yamakawa T, Kurata N, Tsutsuyama M, Umeda S, Tokunaga S, Yarita A, Shibata M, Shimizu D, Shikano T, Hattori K, Mori T, Shinohara M, Miyauchi M. Transumbilical laparoscopic surgery using GelPort through an umbilical zigzag skin incision. Asian J Endosc Surg 2012; 5:50-2. [PMID: 22776345 DOI: 10.1111/j.1758-5910.2011.00113.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
INTRODUCTION We report herein a new method of transumbilical laparoscopic surgery using a GelPort through an umbilical zigzag skin incision. The method involves collaborating with plastic surgeons to ensure the procedure was minimally invasive. MATERIALS AND SURGICAL TECHNIQUE After marking a zigzag skin incision in the umbilical region, the skin was incised along this line. Then, a GelPort double-ring wound retractor was inserted through the incision, which enlarged the diameter of the fascial opening to 6 cm. The Gelport was latched on the wound retractor ring, following the inflation of the pneumoperitoneum by CO (2). One or more additional ports were inserted as necessary. All operations were performed in the standard fashion. The specimen was easily extracted from the abdomen through the umbilical incision, and anastomosis was performed. Using the above method, we performed the following procedures: one total gastrectomy, one distal gastrectomy, three gastric local resections, five right hemicolectomies, two high anterior resections, three cholecystectomies, and seven transabdominal preperitoneal hernioplasties. All cases were accomplished without any complications using this method. The wounds of the umbilical region were almost "scarless" in all cases. DISCUSSION We developed an umbilical zigzag skin incision technique to perform abdominal laparoscopic operations using a GelPort, with a minimal number of skin incisions. We consider that our method reduces the technical difficulties associated with laparoscopic surgery and maintains cosmesis.
Collapse
Affiliation(s)
- T Hachisuka
- Department of General Surgery, Yokkaichi Municipal Hospital, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Ogawa M, Nagao D, Mori K, Sato M, Sato A, Shimizu D, Terada Y. Elastography for differentiation of subchorionic hematoma and placenta previa. Ultrasound Obstet Gynecol 2012; 39:112-114. [PMID: 21728207 DOI: 10.1002/uog.9084] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
35
|
Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, Kawachi K, Nozawa A, Chishima T, Kimura M, Ichikawa Y, Endo I. P5-13-23: Individualized Treatment Strategies for HER2−Negative Breast Cancer Subtypes. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Human epidermal growth factor receptor (HER2)-negative breast cancers are more heterogeneous than HER2−positive cancers, and tailored treatment is therefore required for luminal A and triple-negative breast cancer subtypes (LABC and TNBC). We therefore examined predictive factors for the efficacy of standard chemotherapy in LABC and TNBC subtypes.
Methods A total of 109 LABC and 61 TNBC patients were treated with standard neoadjuvant chemotherapy (NAC) consisting of an anthracycline and/or taxane. The pathological treatment response and prognosis were examined for each subtype. Expression levels of the following factors were examined in association with quasi-pathological complete response (QpCR): estrogen- and progesterone-receptor (ER and PgR) status, HER2, nuclear grade, MIB-1, p53, topoisomerase IIα (topoIIα), cytokeratin (CK) 5/6 and epidermal growth factor (EGFR).
Results QpCR rates in LABC and TNBC were 9.1% (10/109) and 54.1% (33/61), respectively. In LABC, the expression of PgR tended to be inversely associated with pathological response (p=0.087), while in TNBC, increased expression of topoIIa (p=0.006) and MIB-1 (p=0.018) were identified as predictors of QpCR. TopoIIα expression was also significantly associated with pathological response in multivariate analysis (p=0.014). The QpCR rate was higher in TNBC lacking CK5/6 and/or EGFR expression, defined as non-basal subtype (p=0.053).
Conclusions Low expression of PgR may be a possible predictor of the efficacy of chemotherapy in LABC, while a high level of proliferative activity, indicated by topoIIa and MIB-1, is associated with chemosensitivity in TNBC. Further subclassification into basaland non basal-subtypes may also be helpful for the development of individualized treatments.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-23.
Collapse
Affiliation(s)
- T Ishikawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - D Shimizu
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Yamada
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Sasaki
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Morita
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Tanabe
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Kawachi
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Nozawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Chishima
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Kimura
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Ichikawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - I Endo
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| |
Collapse
|
36
|
Yamada A, Chishima T, Kimura M, Shimizu D, Hasegawa S, Ishikawa T, Endo I. Abstract P1-01-16: Evaluation of Sentinel Node Biopsy Using a Combined Dye and Fluorescence Method for Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-01-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sentinel lymph node (SLN) dissection is now widely accepted for staging the axilla in patients with breast cancer. At present, several methods are used to detect SLN. A combination of blue dye and radioactive colloid has been described previously as a superior method for detecting SLN in breast cancer patients. However, use of radioactive colloids is not generally available for various reasons in Japan. SLN detection guided by indocyanine green (ICG) fluorescence could emerge as a new method for SLN biopsy. The aim of this study was to evaluate sentinel node biopsy using a combined dye and fluorescence method for breast cancer.
Methods: Fifty-eight patients with clinically node-negative breast cancer were examined between April 2008 and March 2009 at Yokohama City University Hospital. Intradermal injections of 20 mg/5 ml of indigo carmine and 0.5 mg/0.1 ml of ICG were made into the upper-lateral region of the periareolar area. Subcutaneus lymphatic channels draining from the areola to the axilla were visible under fluorescence within a few minutes. SLNs were then dissected under direct vision supported by fluorescence navigation. Palpable lymph nodes were also dissected. All SLNs were histologically evaluated by 2-mm serial section and staining with hematoxylin and eosin. Patients with positive SLNs underwent axillary lymph node dissection (ALND), while patients with negative SLN did not.
Results: SLNs were identified in 58 patients (100%). ICG fluorescence imaging was compared with indigo carmine dye, and SLNs were identified in 57 and 52 patients, respectively (detection rate: ICG, 98.3%; dye, 89.7%). The mean number of excised SLNs was 2.72. Mean numbers of lymph nodes showing fluorescence and blue stain from injected dye were 2.31 and 1.41, respectively. Eight of 58 patients (13.8%) had metastases detected in the SLN, so ALND were subsequently performed. Five of these cases were without metastases at non-SLN that were dissected. One patient showed metastasis in a SLN that was positive for fluorescence, but negative for blue dye. Among all cases, 1 patient (1.7%) showed an SLN without fluorescence or blue staining, and this case was detected by palpation only.
Conclusion: Combined use of dye and fluorescence method identified SLNs effectively.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-16.
Collapse
Affiliation(s)
- A Yamada
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - T Chishima
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - M Kimura
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - D Shimizu
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - S Hasegawa
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - T Ishikawa
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| | - I. Endo
- Yokohama City University Hospital, Kanagawa, Japan; Yokohama City University Medical Center, Kanagawa, Japan
| |
Collapse
|
37
|
Shimizu D, Ishikawa T, Yamada A, Tanaabe M, Chishima T, Sasaki T, Endo I. Abstract P1-12-01: Preoperative Endocrine Therapy with Tamoxifen and Goserelin Acetate for Hormone Receptor-Positive Premenopausal Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-12-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Clinical trials have consistently shown that the response rates of hormone receptor-positive breast cancer patients to neoadjuvant chemotherapy are low. Preoperative endocrine therapy has therefore become a logical alternative for such patients. Several researchers have reported favorable response rates in postmenopausal women. However, the effectiveness of preoperative endocrine therapy for premenopausal women remains unknown. The aim of this study was to evaluate the potential benefits of preoperative endocrine therapy for premenopausal women.
Materials and methods: Forty premenopausal patients with operable estrogen receptor (ER)-positive breast cancer were consecutively treated with neoadjuvant therapy with tamoxifen and Goserelin acetate for 3 months. The patients eligible for this study included clinically node-negative patients with tumors that were less than 2 cm in diameter and negative for human epidermal growth factor receptor 2 (HER2). All the patients were clinically evaluated using ultrasonograpy before and after the endocrine therapy. Further, core-needle biopsy specimens obtained before administration of the endocrine therapy and surgical specimens were pathologically evaluated for ER, progesterone receptor (PgR), HER2, p53, and Ki67 expressions. This study was approved by our institutional IRB.
Results: The patients included in this study were 30-52 years old (median age, 43 years). The size of the tumor was 0.9-2.0 cm (median, 1.5 cm).
The clinical response rate was 20% (8/40) and disease progression was not observed. In the case of 39 of the 40 patients, grade 0 or grade 1 pathological response was observed. Clinical responses were not correlated with pathological responses. The ER expression level before the endocrine therapy differed from that after the therapy in the case of 8% (2/40) of the patients (increased in 4% and decreased in 4%). Further, PgR expression was altered in the case of 50% (20/40) of the patients (increased in 8% and decreased in 42%). Moreover, Ki67 expression was decreased in 90% (36/40) of the patients after the endocrine therapy.
Conclusions: This is the first report on neoadjuvant endocrine therapy for premenopausal patients. Disease progression 3 months after the endocrine therapy was not observed. Because the expressions of Ki67 and PgR decreased, these molecules might be candidate markers of endocrine responsiveness in premenopausal patients. To confirm this assumption, further evaluations involving tumors of a larger size, longer observational period, and more number of eligible patients are planned to be conducted.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-12-01.
Collapse
Affiliation(s)
- D Shimizu
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - T Ishikawa
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - A Yamada
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - M Tanaabe
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - T Chishima
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - T Sasaki
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| | - I. Endo
- Yokohama City University Medical Center, Kanagawa, Japan; Yokohama City University, Kanagawa, Japan
| |
Collapse
|
38
|
|
39
|
Ishikawa T, Shimizu D, Sasaki T, Morita S, Tanabe M, Ota I, Kawachi K, Nozawa A, Chishima T, Ichikawa Y, Endo I, Shimada H. A Human Epidermal Growth Factor Receptor 2 Expression-based Approach to Neoadjuvant Chemotherapy for Operable Breast Cancer. Jpn J Clin Oncol 2010; 40:620-6. [DOI: 10.1093/jjco/hyq020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Abstract
e16576 Background: Endometrial stromal sarcomas (ESS) traditionally have been classified as low grade or high grade based on mitotic activity and histologic appearance. High-grade tumors are currently referred to as undifferentiated uterine sarcomas and are not included in this series. ESS are known to have high expression of estrogen and progesterone receptors. This is a retrospective study of patients with metastatic ESS treated with hormonal therapy. Methods: Following approval by the institutional review board all patients diagnosed with ESS from 1987–2007 were identified. Clinical and demographic information were abstracted from the charts and all histologic materials were re-reviewed. Estrogen and progesterone receptor testing was performed utilizing mouse monoclonal antibodies and the Cell Analysis Systems 200 Image analyzer. Survival was calculated using the Kaplan-Meier method and comparisons utilized the log rank test. Results: Thirteen patients with ESS were identified during this period. Seven had disease confined to the uterus. Six had extrauterine disease; 5 patients presented with metastases and 1 patient presented with a pelvic recurrence 20 years following a hysterectomy. All underwent surgical resection except for 1 patient that declined surgery. All 6 patients with metastases had tumors that tested positive for estrogen and progesterone receptors; all were treated with megestrol acetate initially for a period of 1–4 years. Two patients were then changed to maintenance with medroxyprogesterone acetate. Three patients with persistent disease were changed to aromatase inhibitors; 1 to letrozole and 2 to anastrazole. One of these patients has had a complete response and 2 have had stable disease. One patient has been lost to follow-up. Follow-up for the 6 patients was 2–22 years; no known patients died of their disease. Actuarial 2- and 5-year survivals were 80% and 65%, respectively. There was no significant difference in survival between patients with metastases and without metastases. Conclusions: ESS tumors are relatively uncommon and there is an absence of studies to guide treatment of patients with metastases. This experience indicates that these tumors respond well to hormonal manipulation. Treatment with progestins or aromatase inhibitors may result in remission or stable disease. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Y. Terada
- University of Hawaii, Honolulu, HI; Cancer Research Center, Honolulu, HI; Department of Pathology, Queens Medical Center, Honolulu, HI
| | - J. Davis
- University of Hawaii, Honolulu, HI; Cancer Research Center, Honolulu, HI; Department of Pathology, Queens Medical Center, Honolulu, HI
| | - J. Kitayama
- University of Hawaii, Honolulu, HI; Cancer Research Center, Honolulu, HI; Department of Pathology, Queens Medical Center, Honolulu, HI
| | - D. Shimizu
- University of Hawaii, Honolulu, HI; Cancer Research Center, Honolulu, HI; Department of Pathology, Queens Medical Center, Honolulu, HI
| |
Collapse
|
41
|
Vallböhmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A, Danenberg PV. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2007; 31:413-8. [PMID: 17611699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023] Open
Abstract
Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU). However, there are no validated and established predictive factors for clinical outcome of capecitabine efficacy in CRC. The gene expressions of the pyrimidine metabolism enzymes dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and thymidylate synthase (TS) have previously been shown to be response determinants of fluoropyrimidine-based drugs in various tumors. Therefore, we investigated whether intratumoral mRNA expression levels of these genes are also associated with the clinical outcome of patients with metastatic CRC treated with first-line capecitabine. Thirty-seven patients with metastatic CRC were enrolled in this study and treated with single agent capecitabine. The intratumoral mRNA levels of DPD, TP and TS were assessed from paraffin-embedded tissue samples using laser-capture-microdissection methods and quantitative real-time PCR. There were 20 women and 17 men with a median age of 61 years (range 49-74). The median progression-free survival was 6.7 months (95% CI, 4.8-11.6 months), with a median follow-up of 14.4 months (range 1.3-18.7 months). Complete response was observed in 1 (3%), partial response in 6 (20%), stable disease in 14 (47%) and progressive disease in 9 (30%) patients (response was inevaluable in 7 patients). Higher gene expression levels of DPD were associated with resistance to capecitabine (P=0.032; Kruskal-Wallis test). Patients with a lower mRNA amount of DPD (<or=0.46) had a longer progression-free survival compared with patients that had a higher mRNA amount (8.0 vs. 3.3 months; adjusted P=0.048; log-rank test). This pilot study suggests that intratumoral gene expression levels of DPD may be useful in predicting the clinical outcome of patients with metastatic CRC with first-line single agent capecitabine treatment. Our data should be validated in larger and prospective clinical trials.
Collapse
Affiliation(s)
- Daniel Vallböhmer
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Vallböhmer D, Yang D, Kuramochi H, Shimizu D, Danenberg K, Lindebjerg J, Nielsen J, Jakobsen A, Danenberg P. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2007. [DOI: 10.3892/ijo.31.2.413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
43
|
Vallböhmer D, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A, Danenberg PV. Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol 2007; 28:527-33. [PMID: 16391809 DOI: 10.3892/ijo.28.2.527] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) are predictive markers for tumor response to 5-fluorouracil-based therapies. To determine whether gene expression values measured in primary cancer tissue would be useful for prediction of response of lymph node metastases, the expressions of these genes were quantitatively analyzed in 35 pairs of primary colorectal cancer (CRC) and corresponding lymph node metastases using real-time PCR. DPD and TP mRNA levels were significantly lower in the primary colorectal tumor and lymph node metastases compared with the normal adjacent stroma tissue (p<0.01), whereas TS mRNA levels were significantly higher in the primary tumor and lymph node metastases than in the normal adjacent tissue (p<0.001). Median gene expression levels of TP and TS did not differ significantly between primary colorectal tumor and corresponding lymph node metastasis but median DPD gene expression levels in the lymph node metastases were significantly higher compared to matched primary colorectal tumors (p=0.015). There was a significant correlation for DPD, TP and TS gene expression levels between primary colorectal tumor specimens and the matched lymph node metastasis. These results suggest that biopsies of the tumor of origin may be valid for determining predictive markers for chemotherapy response in patients with metastatic CRC.
Collapse
Affiliation(s)
- D Vallböhmer
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Vallböhmer D, DeMeester SR, Peters JH, Oh DS, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, DeMeester TR, Chandrasoma PT. Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis Esophagus 2006; 19:260-6. [PMID: 16866857 DOI: 10.1111/j.1442-2050.2006.00586.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The molecular pathogenesis of Barrett's esophagus is poorly understood. Evidence suggests that at a phenotypic level, the metaplastic process begins with the transformation of squamous epithelium in the distal esophagus to cardiac mucosa, which subsequently becomes intestinalized. The homeobox gene Cdx-2 has been shown to be an important transcriptional regulator of embryonic differentiation and maintenance of adult intestinal type epithelium. We hypothesized that Cdx-2 gene expression levels increase with the phenotypic transformation of normal squamous mucosa to the intestinalized columnar mucosa of Barrett's esophagus. Endoscopic biopsies were obtained at the gastroesophageal junction in patients with symptoms of gastroesophageal reflux disease and classified according to histology: normal squamous mucosa (n = 62), cardiac mucosa (n = 19), oxynto-cardiac mucosa (n = 14), and intestinal metaplasia (n = 15). Duodenal biopsies (n = 26) served as the columnar control. After laser capture microdissection and RNA isolation, gene expression levels of Cdx-2 were measured in each tissue type by quantitative reverse transcription polymerase chain reaction. Consistent with its known function, Cdx-2 gene expression levels were highest in duodenal mucosa and nearly absent in squamous epithelium. There was a stepwise increase in Cdx-2 gene expression from cardiac to Barrett's epithelium (P < 0.001). Expression levels of Cdx-2 in cardiac and oxynto-cardiac mucosa were 40-70 times higher and Barrett's mucosa 400 times higher than that found in squamous epithelium. Relative expression of the homeobox gene Cdx-2, known to induce differentiation of intestinal type epithelium, increases in a stepwise fashion during the phenotypic transformation of distal esophageal squamous mucosa to cardiac columnar mucosa and to the intestinalized columnar mucosa of Barrett's esophagus. Therefore, Cdx-2 may be a potential biomarker to detect the early transition to Barrett's esophagus.
Collapse
Affiliation(s)
- D Vallböhmer
- Department of Surgery, University of Southern California, Los Angeles, 90033, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Shimizu D, Kuramochi H, Tanaka K, Cooc J, Xiong Y, William M, Li R, Danenberg KD, Danenberg PV, Lenz HJ. Molecular signatures generated with RNA isolated from formalin-fixed paraffin-embedded tumor specimens differentiate metastatic and non-metastatic primary colorectal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3615 Background: Colorectal cancer (CRC) can be either non-metastatic (locally-advanced) or metastatic, with the latter having a considerably worse prognosis. Because tissue from patients is generally available only as FFPE specimens, we investigated whether distinct molecular signatures could be obtained for these CRC types using RNA isolated from archival FFPE specimen blocks in gene expression arrays. Methods: FFPE specimens were available from 12 non-metastatic tumors and 9 primary tumors along with their matching metastases. Up to 5 10-micron sections of each were microdissected to isolate areas of tumor tissue. RNA was extracted using a proprietary procedure of Response Genetics, Inc. and was then amplified and labeled. The resulting cRNA was hybridized to the U133 plus 2.0 GeneChip. Unsupervised PCA analysis of the samples resulted in the first principal component separating 2 distinct groups, which consisted of the non-metastatic and metastatic tumors. A differentially expressed gene list between metastatic and non-metastatic CRC was determined. These data were also analyzed for differential canonical pathways using Ingenuity Pathway Analysis. Results: Hierarchical clustering analysis segregated locally advanced primary tumors and metastatic primary tumors into two clusters with distinct gene signatures. A T-test with unequal variance assumption identified 609 differentially expressed probe sets with FDR (false discovery rate) = 0.05. Comparison of primary tumors with their liver metastases using a paired T-test showed only 2 differentially expressed genes at FDR = 0.05 but 526 genes with significance p value < 0.005. Pathway analysis showed significant deregulation of VEGF, hypoxia, B Cell receptor, PI3K/AKT, ERK/MAPK and G-protein coupled receptor signaling between locally advanced and metastatic tumors. Pathway analysis of primary tumors and metastases showed deregulated TGF-b, integrin and chemokine signaling pathways. Conclusion: We have demonstrated the feasibility of identifying metastatic and non-metastatic tumors by microarray analysis using FFPE CRC tissue. This result is currently being validated in a separate larger cohort of patients. [Table: see text]
Collapse
Affiliation(s)
- D. Shimizu
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - H. Kuramochi
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - K. Tanaka
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - J. Cooc
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - Y. Xiong
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - M. William
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - R. Li
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - K. D. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - P. V. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - H. J. Lenz
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| |
Collapse
|
46
|
Joshi MM, Petersen RP, Conlon DH, Tanaka K, Shimizu D, Kuramochi H, Williams M, Danenberg PV, Danenberg KD, Harpole DH. Differential canonical pathways derived from microarrays using RNA from paraffin-embedded non-small cell lung cancer tissue. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7226 Background: Several molecular targets have been approved for use in patients with non-small cell lung cancer (NSCLC) and several hundred are in various phases of investigation. However, the efficacy of these targets range from 5–15% of the overall population of NSCLC patients. Therefore, the challenge remains to appropriately match the most active target with the individual patient. Our goal was to investigate a novel strategy for identifying active pathways from formalin-fixed, paraffin-embedded (FFPE) NSCLC samples. Methods: Ten 5 um sections of FFPE tumor were collected from 66 NSCLC patients consisting of equal numbers of long- (+5-year) and short-term (<2 year cancer death) survivors. Sixty samples were microdissected (6 samples contained no tumor tissue) and RNA was extracted using a proprietary procedure of Response Genetics, Inc. Amplification and labeling of RNA were done using the Affymetrix two cycle amplification kit. Resulting cRNA was hybridized to the U133 plus 2.0 GeneChip. A differentially expressed gene list between long and short survivors was determined. These data were also analyzed for differential canonical pathways using Ingenuity Pathway Analysis. Results: We identified the differential pathways indicated by the unique gene signatures between early stage patients surviving <2 yrs and >2 yrs for both adenocarcinomas and squamous cell carcinomas. Adenocarcinoma pathways that differed between short- and long-term survivors were: G2M DNA damage checkpoint, EGF, estrogen receptor, hypoxia, VEGF, PDGF, IL-6 JAK/Stat and neurotrophin/Trk signaling. In contrast, for squamous cell carcinomas the main differing pathways were: Wnt/b-catenin signaling and retinol metabolism. Conclusions: We have demonstrated the feasibility of generating differential canonical pathways from FFPE NSCLC specimens which may serve as a tool to guide selection of molecular targets for the individual patient. In addition, these pathways may be a rational method for selecting the correct subset of patients most likely to respond to agents being investigated in early phase clinical trials. These data require validation in a larger prospective study. [Table: see text]
Collapse
Affiliation(s)
- M. M. Joshi
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - R. P. Petersen
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - D. H. Conlon
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - K. Tanaka
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - D. Shimizu
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - H. Kuramochi
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - M. Williams
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - P. V. Danenberg
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - K. D. Danenberg
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| | - D. H. Harpole
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA; Response Genetics, Inc, Los Angeles, CA
| |
Collapse
|
47
|
Tanaka K, Shimizu D, Kuramochi H, Cooc J, Williams M, Li R, Chen P, Danenberg KD, Danenberg PV, Lenz HJ. Molecular signatures generated with RNA Isolated from formalin-fixed paraffin-embedded tumor specimens differentiate metastatic and non-metastatic primary breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
614 Background: Breast cancer can be either non-metastatic (locally-advanced) or metastatic, with the latter giving rise to a considerably worse prognosis. Because tissue from patients is generally available only as FFPE specimens, we investigated whether distinct molecular “signatures” could be obtained for these breast cancer types using RNA isolated from archival FFPE specimen blocks in gene expression arrays. Methods: FFPE specimens were available from 15 non-metastatic tumors and 12 primary tumors along with their matching metastases. Up to 5 10-micron sections of each were microdissected to isolate areas of tumor tissue. RNA was extracted using a proprietary procedure of Response Genetics, Inc. and was then amplified and labeled. The resulting cRNA was hybridized to the U133 plus 2.0 GeneChip. An unsupervised PCA analysis of the samples resulted in the first principal component separating 2 distinct groups which consisted of the non-metastatic and metastatic tumors. A differentially expressed gene list between metastatic and non-metastatic CRC was determined. These data were also analyzed for differential canonical pathways using Ingenuity Pathway Analysis. Results: Hierarchical clustering analysis segregated locallyadvanced primary tumors and metastatic primary tumors intotwo clusters with distinct gene signatures. A T-test with unequal variance assumption identified 1595 differentially expressed probe sets with FDR (false discovery rate) = 0.005 (p=0.00015). However, comparison of primary tumors with their liver metastases using a paired T-test showed only 18 differentially expressed probe sets at FDR=0.05 and 1019 genes with significance p value ≤ 0.005. Pathway analysis showed significant deregulation of FGF signaling, G2/M DNA damage cell cycle checkpoint, IL-2, IL-4 and EGF signaling between locally advanced and metastatic primary tumors. Conclusion. We have demonstrated the feasibility of identifying metastatic and non-metastatic tumors by microarray analysis using FFPE breast cancer tissue. This result is currently being validated in a separate larger cohort of patients. [Table: see text]
Collapse
Affiliation(s)
- K. Tanaka
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - D. Shimizu
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - H. Kuramochi
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - J. Cooc
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - M. Williams
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - R. Li
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - P. Chen
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - K. D. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - P. V. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| | - H. J. Lenz
- University of Southern California, Los Angeles, CA; Response Genetics Inc., Los Angeles, CA; Roche Molecular Diagnostics, Pleasanton, CA
| |
Collapse
|
48
|
Harpole DH, Joshi MM, Petersen RP, Conlon DH, Tanaka K, Shimizu D, Kuramochi H, Williams M, Danenberg PV, Danenberg K. A lung cancer genomic risk prediction model derived from paraffin-embedded tissue. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10059 Background: We previously developed a validated fresh tissue-based genomic risk model in patients with early stage non-small cell lung cancer (NSCLC) using the Affymetrix U133 plus 2.0 Genechip. Limitations of this fresh tissue-based model include the need for immediate processing and limited availability; however, formalin-fixed, paraffin-embedded (FFPE) tissue is readily available and archived on every patient resected in North America. We investigated the ability of gene expression profiles generated on DNA microarrays using RNA isolated from FFPE NSCLC specimens to distinguish short-term and long-term survivors. Methods: Five to ten 5 um sections of FFPE tumor were collected from 61 NSCLC patients consisting of equal numbers of long- (+5-year) and short-term (<2 year cancer death) survivors. Fifty-five samples were microdissected (6 samples contained no tumor tissue) and RNA was extracted using a proprietary procedure of Response Genetics, Inc. For this feasibility study, Actin 300 < 30 cTs was chosen as a threshold for adequate RNA quantity for amplification to the GeneChip. Amplification and labeling of RNA were done using the Affymetrix two cycle amplification kit. The resulting cRNA was successfully hybridized to the U133 plus 2.0 GeneChip in 54/55 samples (98%). Data were analyzed using the SAM statistical software with Kaplan Meier survival analyses. Results: All analyses were performed using unsupervised hierarchical clustering and blinded duplicate samples had nearly identical gene expression profiles, indicating reproducibility. Adenocarcinoma segregated from squamous cell carcinoma with 98% accuracy (p=0.00004). A differentially expressed gene list between long and short survivors was determined. Distinct gene clusters were observed within each histological type segregating the tumors according to outcome. Kaplan Meier survival analysis stratifying on these clusters revealed significant differences in survival (cluster 1 and cluster 2 median survival>75 mos. vs. 30 mos., respectively; p<0.001). Conclusions: We have demonstrated the feasibility of creating a preliminary genomic risk prediction model using FFPE NSCLC tissue. Data will be presented on a larger training set (100+ patients) and a separate validation cohort of 100 patients. [Table: see text]
Collapse
Affiliation(s)
- D. H. Harpole
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - M. M. Joshi
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - R. P. Petersen
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - D. H. Conlon
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - K. Tanaka
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - D. Shimizu
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - H. Kuramochi
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - M. Williams
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - P. V. Danenberg
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| | - K. Danenberg
- Duke University Medical Center, Durham, NC; University of Southern California, Los Angeles, CA; Roche Molecular Systems, Pleasanton, CA; Response Genetics, Inc., Los Angeles, CA
| |
Collapse
|
49
|
Vallbohmer D, Kuramochi H, Shimizu D, Danenberg KD, Nielsen JN, Lindebjerg J, Jakobsen A, Danenberg PV. Molecular determinants of capecitabine efficacy in colorectal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3606 Background: Capecitabine offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU). However, there are no validated and established predictive factors for clinical outcome of capecitabine efficacy in CRC. Therefore we investigated whether intratumoral mRNA expression levels of genes involved in the capecitabine/5-FU metabolism (cytidine deaminase (CDA), dihydropyrimidine dehydrogenase (DPD), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), thymidine phosphorylase (TP), thymidylate synthase (TS)) and in angiogenesis (cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)) are associated with the clinical outcome of patients with metastatic CRC treated with first-line capecitabine. Methods: Thirty-seven patients with metastatic CRC were enrolled in this study and treated with single agent capecitabine.The intratumoral mRNA levels of CDA, COX-2, DPD, EGFR, FPGS; GGH, TP, TS, and VEGF were assessed from paraffin-embedded tissue samples using laser-capture-microdissection methods and quantitative real-time PCR. Results: There were20 women and 17 men with a median age of 61 years (range 49–74). The median progression-free survival was 6.7 months (95% CI, 4.8–11.6 months), with a median follow up of 14.4 months (range: 1.3 to 18.7 months). Complete response was observed in 1 (3%), partial response in 6 (20%), stable disease in 14 (47%) and progressive disease in 9 (30%) patients (response was inevaluable in 7 patients). Higher gene expression levels of DPD were associated with resistance to capecitabine (P= 0.032; Kruskal-Wallis test). Patients with a lower mRNA amount of DPD (≤0.46) had a longer progression-free survival compared with patients that had a higher mRNA amount (8.0 vs. 3.3 months; adjusted P=0.048; log-rank test). Conclusions: This pilot study suggests that intratumoral gene expression levels of DPD may be useful to predict the clinical outcome of patients with metastatic CRC with first-line single agent capecitabine treatment. Our data are hypothesis generating and should be validated in larger and prospective clinical trials. [Table: see text]
Collapse
Affiliation(s)
- D. Vallbohmer
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - H. Kuramochi
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - D. Shimizu
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - K. D. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - J. N. Nielsen
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - J. Lindebjerg
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - A. Jakobsen
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| | - P. V. Danenberg
- University of Southern California, Los Angeles, CA; Response Genetics, Inc., Los Angeles, CA; University of Southern Denmark, Vejle, Denmark
| |
Collapse
|
50
|
Kuramochi H, Hayashi K, Uchida K, Shimizu D, Vallboehmer D, Park SJ, Miyakura S, Danenberg KD, Takasaki K, Danenberg PV. 5-fluorouracil related gene expression levels in primary colorectal cancer and corresponding liver metastases. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3568] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Kuramochi
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - K. Hayashi
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - K. Uchida
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - D. Shimizu
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - D. Vallboehmer
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - S. J. Park
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - S. Miyakura
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - K. D. Danenberg
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - K. Takasaki
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| | - P. V. Danenberg
- Univ of Southern CA, Los Angeles, CA; Tokyo Women’s Medcl Univ, Tokyo, Japan; Response Genetics, Los Angeles, CA
| |
Collapse
|